RUFFOLO ROBERT R 4
4 · LB PHARMACEUTICALS INC · Filed Sep 12, 2025
Insider Transaction Report
Form 4
RUFFOLO ROBERT R
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-09-10+717→ 717 totalExercise: $15.00Exp: 2030-08-24→ Common Stock (717 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-09-10−1,792→ 0 totalExercise: $69.72Exp: 2028-06-26→ Common Stock (1,792 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-09-10−717→ 0 totalExercise: $69.72Exp: 2030-08-24→ Common Stock (717 underlying) - Award
Stock Option (Right to Buy)
2025-09-10+10,757→ 10,757 totalExercise: $15.00Exp: 2034-03-03→ Common Stock (10,757 underlying) - Award
Stock Option (Right to Buy)
2025-09-10+1,792→ 1,792 totalExercise: $15.00Exp: 2028-06-26→ Common Stock (1,792 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-09-10−10,757→ 0 totalExercise: $41.84Exp: 2034-03-03→ Common Stock (10,757 underlying) - Award
Stock Option (Right to Buy)
2025-09-10+22,449→ 22,449 totalExercise: $15.00Exp: 2035-09-09→ Common Stock (22,449 underlying)
Footnotes (4)
- [F1]Immediately exercisable.
- [F2]The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
- [F3]One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- [F4]The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.